secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001193125-23-069935
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru refocuses on sabizabulin for COVID/influenza; terminates prostate cancer trial, pauses two assets
--------------------------------------------------------------------------------

- Terminating Phase 3 VERACITY trial of sabizabulin in prostate cancer; pausing Phase 2 Veru-100 and zuclomiphene development.
- Plans Phase 3 confirmatory study of sabizabulin for hospitalized moderate/severe COVID-19 patients at high risk for ARDS.
- Plans Phase 3 study of sabizabulin for hospitalized influenza patients at high risk for ARDS.
- Updated Phase 3 ENABLAR-2 study of enobosarm + abemaciclib for second-line metastatic breast cancer; rolling ARTEST into it pending FDA/Lilly approval.
- Cash conservation measures including personnel reduction; prior FDA denial of EUA for sabizabulin on March 2, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312523069935/0001193125-23-069935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312523069935/d254341d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-069935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer